ClinicalTrials.gg
CompletedNCT05631704Updated Dec 29, 2025

A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity

A Phase 1 interventional study of VH4524184 and Midazolam in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
105th of 210
84 · median 82
Started
2022
with 5 others
Phase 1
83 of 266
9 open now
Registered
231st of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 105th largest by enrollment of the 210 interventional ones that give a count, is one of 6 that started in 2022, is one of 83 in phase 1, and was the 231st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study is designed to investigate the safety, tolerability and PK of VH4524184 (GSK4524184) and the potential of VH4524184 to inhibit or induce CYP3A activity in healthy participants.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • First-time-in-human
  • GSK4524184
  • Healthy volunteers
  • Multiple Ascending Dose
  • Single Ascending Dose
  • VH4524184
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 50 years of age.
  • Participants who are overtly healthy.
  • Body weight >=50.0 kilograms (kg) (110 pounds [lbs]) for men and >=45.0 kg (99 lbs) for women and within the range 18.5 to 32.0 kilograms per meter square (kg/m\^2) (inclusive).
  • Male or female. Male Participants: No restrictions for male participants. Female Participants: A female participant (female sex assigned at birth) is eligible to participate if she is not pregnant, or breastfeeding and is not physically able to have a baby.

Exclusion criteria

Exclusion Criteria:

  • History or presence of clinical condition that could significantly alter how medicines are absorbed, broken down or eliminated from the body; be risky to the participant, or make it difficult to interpret the data from the study.
  • Pre-existing gastro-intestinal disorders.
  • Abnormal blood pressure.
  • Certain blood or other cancers within the past 5 years.
  • Breast cancer within the past 10 years
  • Current or chronic history of liver disease or liver or bile tract abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • corrected for heart rate according to Fridericia's formula (QTcF) >450 milliseconds (msec).
  • Medical history of cardiac arrhythmias or cardiac disease or a family and personal history of long QT syndrome.
  • History of seizure
  • Any known or suspected pre-existing psychiatric condition, including depression, anxiety and insomnia/sleep disturbances.
  • Any positive (abnormal) response to the Columbia Suicide Severity Rating Scale (CSSRS).
  • Past or intended use of over-the-counter or prescription medication within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study.
  • Receipt of any (s) or vaccines against Coronavirus disease 2019 (Covid-19) within 28 days prior to screening or plans to receive such vaccines during the study.
  • Exposure to more than 4 new products (including long-acting investigational products) within 12 months prior to the first dosing day.
  • Current enrollment or past participation in another investigational study in which an investigational intervention (e.g., drug, human blood product, monoclonal antibody, vaccine, invasive device) was administered within the last 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) before signing of consent (OR screening) any other clinical study.
  • Participation in the study would result in loss of blood or blood products in excess of 500 milliliters (mL) over a 56-day period.
  • Current enrollment or past participation in this clinical study.
  • Estimated (eGFR) \<90 milliliters per minute (mL/min) (calculated using Chronic Kidney Disease Epidemiology Collaboration equation) or serum creatinine >1.1 times (ULN).
  • \<12.5 grams per deciliter (g/dL) for men and \<11 g/dL for women
  • or AST >1.5 times ULN
  • Total >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35 percent [%]).
  • Any significant arrhythmia or (ECG) finding
  • Exclusion criteria for Screening ECG (a single repeat is allowed for eligibility determination): Heart rate:\<45 or >100 beats per minute (bpm) (Males), \<50 or >100 bpm (Females); PR interval: \<120 or >220 msec; QRS duration: \<70 or >120 msec and QTcF interval: >450 msec.
  • Presence of surface antigen (HBsAg) at screening.
  • Positive antibody test result at screening
  • Positive pre-study drug/alcohol screen.
  • Positive (HIV) antibody test.
  • Regular alcohol consumption within 6 months prior to the study
  • Regular use of known drugs of abuse
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening and at admission.
  • Sensitivity to the study drug, or components thereof, midazolam (For Part 2, midazolam probe cohort), contained therein, benzodiazepines, or other drug or other allergy that, in the opinion of the investigator or Sponsor Medical Monitor, contraindicates participation in the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Part 1: Cohort 1: Participants receiving VH4524184 DL1

    Eligible participants will receive VH4524184 Dose Level 1 (DL1) during Cohort 1 of Part 1 of the study.

    Drug: VH4524184

  • Placebo comparator
    Part 1: Cohort 1: Participants receiving Placebo

    Eligible participants will receive Placebo matching VH4524184 DL1 during Cohort 1 of Part 1 of the study.

    Drug: Placebo

  • Experimental
    Part 1: Cohort 2: Participants receiving VH4524184 DL2

    Eligible participants will receive VH4524184 DL2 during Cohort 2 of Part 1 of the study.

    Drug: VH4524184

  • Placebo comparator
    Part 1: Cohort 2: Participants receiving Placebo

    Eligible participants will receive Placebo matching VH4524184 DL2 during Cohort 2 of Part 1 of the study.

    Drug: Placebo

  • Experimental
    Part 1: Cohort 3: Participants receiving VH4524184 DL3

    Eligible participants will receive VH4524184 DL3 during Cohort 3 of Part 1 of the study.

    Drug: VH4524184

  • Placebo comparator
    Part 1: Cohort 3: Participants receiving Placebo

    Eligible participants will receive Placebo matching VH4524184 DL3 during Cohort 3 of Part 1 of the study.

    Drug: Placebo

  • Experimental
    Part 1: Cohort 4: Participants receiving VH4524184 DL4

    Eligible participants will receive VH4524184 DL4 during Cohort 4 of Part 1 of the study.

    Drug: VH4524184

  • Placebo comparator
    Part 1: Cohort 4: Participants receiving Placebo

    Eligible participants will receive Placebo matching VH4524184 DL4 during Cohort 4 of Part 1 of the study.

    Drug: Placebo

  • Experimental
    Part 1: Cohort 5: Participants receiving VH4524184 DL5

    Eligible participants will receive VH4524184 DL5 during Cohort 5 (optional) of Part 1 of the study.

    Drug: VH4524184

  • Placebo comparator
    Part 1: Cohort 5: Participants receiving Placebo

    Eligible participants will receive Placebo matching VH4524184 DL5 during Cohort 5 (optional) of Part 1 of the study.

    Drug: Placebo

  • Experimental
    Part 1: Cohort 6: Participants receiving VH4524184 DL6

    Eligible participants will receive VH4524184 DL6 during Cohort 6 (optional) of Part 1 of the study.

    Drug: VH4524184

  • Placebo comparator
    Part 1: Cohort 6: Participants receiving Placebo

    Eligible participants will receive Placebo matching VH4524184 DL6 during Cohort 6 (optional) of Part 1 of the study.

    Drug: Placebo

  • Experimental
    Part 2: Cohort 7: Participants receiving VH4524184 RL1

    Eligible participants will receive VH4524184 Repeat dose Level 1 (RL1) during Cohort 7 (Part 2) of the study.

    Drug: VH4524184

  • Placebo comparator
    Part 2: Cohort 7: Participants receiving Placebo

    Eligible participants will receive Placebo matching VH4524184 RL1 during Cohort 7 (Part 2) of the study.

    Drug: Placebo

  • Experimental
    Part 2: Cohort 8: Participants receiving VH4524184 RL2

    Eligible participants will receive VH4524184 RL2 during Cohort 8 (Part 2) of the study. If Cohort 8 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of VH4524184

    Drug: VH4524184 · Drug: Midazolam

  • Placebo comparator
    Part 2: Cohort 8: Participants receiving Placebo

    Eligible participants will receive Placebo matching VH4524184 RL2 during Cohort 8 (Part 2) of the study. If Cohort 8 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of Placebo matching VH4524184.

    Drug: Midazolam · Drug: Placebo

  • Experimental
    Part 2: Cohort 9: Participants receiving VH4524184 RL3

    Eligible participants will receive VH4524184 RL3 during Cohort 9 (Part 2) (optional) of the study. If Cohort 9 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of VH4524184.

    Drug: VH4524184 · Drug: Midazolam

  • Placebo comparator
    Part 2: Cohort 9: Participants receiving Placebo

    Eligible participants will receive Placebo matching VH4524184 RL3 during Cohort 9 (Part 2) (optional) of the study. If Cohort 9 is the highest Part 2 dose cohort, participants may also receive midazolam probe before and following repeat dose administration of Placebo matching VH4524184.

    Drug: Midazolam · Drug: Placebo

  • Experimental
    Part 3: Cohort 10: VH4524184 Fasted/ VH4524184 Fed

    Eligible participants will receive VH4524184 under fasted condition in Treatment Period 1 followed by VH4524184 under fed condition in Treatment Period 2 during Cohort 10 (Part 3) of the study. Treatment Periods will be separated by a washout period.

    Drug: VH4524184

Interventions

  • VH4524184 will be administered.

  • Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).

  • DrugPlacebo

    Placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of participants with serious adverse events (SAE) and non-serious adverse events (non-SAE)

    Time frame: Up to 4 weeks

  2. Part 2: Number of participants with SAE and non-SAE

    Time frame: Up to 6.5 weeks

  3. Part 3: Number of participants with SAE and non-SAE

    Time frame: Up to 6.5 weeks

  4. Part 1: Number of participants with adverse events based on severity

    Time frame: Up to 4 weeks

  5. Part 2: Number of participants with adverse events by severity

    Time frame: Up to 6.5 weeks

  6. Part 3: Number of participants with adverse events based on severity

    Time frame: Up to 6.5 weeks

  7. Part 1: Percentage of participants who discontinue treatment due to adverse events (AE)

    Time frame: Up to 4 weeks

  8. Part 2: Percentage of participants who discontinue treatment due to AE

    Time frame: Up to 6.5 weeks

  9. Part 3: Percentage of participants who discontinue treatment due to AE

    Time frame: Up to 6.5 weeks

  10. Part 1: Change from Baseline in Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) and Alkaline phosphatase (ALP) (International units per liter)

    Time frame: Baseline (Day 1) and up to 4 weeks

  11. Part 2: Change from Baseline in AST, ALT and ALP (International units per liter)

    Time frame: Baseline (Day 1) and up to 6.5 weeks

  12. Part 3: Change from Baseline in AST, ALT and ALP (International units per liter)

    Time frame: Baseline (Day 1) and up to 6.5 weeks

  13. Part 1: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter)

    Time frame: Baseline (Day 1) and up to 4 weeks

  14. Part 2: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter)

    Time frame: Baseline (Day 1) and up to 6.5 weeks

  15. Part 3: Change from Baseline in Total bilirubin and Direct bilirubin (Micromoles per liter)

    Time frame: Baseline (Day 1) and up to 6.5 weeks

  16. Part 1: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds)

    Time frame: Baseline (Day 1) and up to 4 weeks

  17. Part 2: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds)

    Time frame: Baseline (Day 1) and up to 6.5 weeks

  18. Part 3: Change from Baseline in Prothrombin time and Partial Thromboplastin Time (Seconds)

    Time frame: Baseline (Day 1) and up to 6.5 weeks

  19. Part 1: Change from Baseline in International normalized ratio (INR) (Ratio)

    Time frame: Baseline (Day 1) and up to 4 weeks

  20. Part 2: Change from Baseline in INR (Ratio)

    Time frame: Baseline (Day 1) and up to 6.5 weeks

  21. Part 3: Change from Baseline in INR (Ratio)

    Time frame: Baseline (Day 1) and up to 6.5 weeks

  22. Part 1: Number of participants with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INR

    Time frame: Baseline (Day 1) and up to 4 weeks

  23. Part 2: Number of participants with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INR

    Time frame: Baseline (Day 1) and up to 6.5 weeks

  24. Part 3: Number of participant with maximum toxicity grade increase from Baseline in liver panel laboratory parameters; AST, ALT, ALP, Total bilirubin, Direct bilirubin, Prothrombin time, Partial Thromboplastin Time and INR

    Time frame: Baseline (Day 1) and up to 6.5 weeks

  25. Part 1: Area under the plasma-concentration time curve from zero (pre-dose) extrapolated to infinite time (AUC[0-infinity]) following dosing of VH4524184

    Time frame: Up to 4 weeks

  26. Part 2: Area under the plasma concentration-time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-tau]) following dosing of VH4524184

    Time frame: Up to 6.5 weeks

  27. Part 1: Maximum observed plasma drug concentration (Cmax) following dosing of VH4524184

    Time frame: Up to 4 weeks

  28. Part 2: Cmax following dosing of VH4524184

    Time frame: Up to 6.5 weeks

  29. Part 1: Time to maximum observed plasma drug concentration (tmax) following dosing of VH4524184

    Time frame: Up to 4 weeks

  30. Part 2: Tmax following dosing of VH4524184

    Time frame: Up to 6.5 weeks

  31. Part 1: Apparent terminal half-life (t1/2) following dosing of VH4524184

    Time frame: Up to 4 weeks

  32. Part 2: T1/2 following dosing of VH4524184

    Time frame: Up to 6.5 weeks

Secondary outcomes

  1. Part 1: Number of participants with treatment emergent Grade 3 or Grade 4 laboratory abnormalities

    Time frame: Up to 4 weeks

  2. Part 2: Number of participants with treatment emergent Grade 3 or Grade 4 laboratory abnormalities

    Time frame: Up to 6.5 weeks

  3. Part 3: Number of participants with treatment emergent Grade 3 or Grade 4 laboratory abnormalities

    Time frame: Up to 6.5 weeks

07

Study locations

1 site
  • GSK Investigational Site
    Baltimore, Maryland 21225, United States
08

References and documents

Publications

  • Rogg L, Underwood M, Hanan N, Castillo-Mancilla JR, Kahl L, Halliday F, Ghita GL, Jeffrey JL, Byrne S, Onodera T, Horton J, Gartland M. Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clin Infect Dis. 2025 Oct 6;81(3):510-520. doi: 10.1093/cid/ciaf135. PubMed 40117383 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jul 2023, 7 months.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 7 months is above that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2022
First posted
Nov 30, 2022
StartActual
Dec 2, 2022
Primary completionActual
Jul 27, 2023
CompletionActual
Jul 27, 2023
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05631704
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Dec 2, 2022
Primary completion
Jul 27, 2023
Completion
Jul 27, 2023
Last update
Dec 29, 2025

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: VH4524184 · Midazolam

Start the discussion